Navigation Links
A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
Date:6/12/2008

Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources

WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that is more effective than Roche's Xenical at inducing weight loss would earn a 40 percent patient share in the obesity drug market, according to surveyed primary care physicians. Although other efficacy measures-such as the effect on weight maintenance-are also important to prescribers, the biggest unmet need within this indication is a therapy that can consistently induce more than ten percent weight loss. The Food and Drug Administration currently requires that a drug elicit between five and ten percent weight loss to get approval.

The new report entitled Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety finds that Vivus's Qnexa will become Decision Resources' proprietary clinical gold standard by 2011 due to its competitive advantages in efficacy and delivery over the 2006 gold standard, Xenical. By 2016 however, Orexigen's Empatic will supersede Qnexa due to its advantage in safety. Both Empatic and Qnexa are fixed dose combinations of currently marketed central nervous system agents used for indications like epilepsy, alcohol dependence and depression.

"Phase II clinical trial data revealed that Qnexa caused a greater overall weight reduction compared with pooled data for Xenical after a 24-week treatment period," said Donny Wong, Ph.D., principal analyst at Decision Resources. "According to physicians we surveyed, Empatic's overall score for safety and tolerability is better, based on the perception that this combination agent is more conducive to longer-term treatment."

About the Report

Obesity: Current Pipeline Falls Short of Physicians' Expectations fo
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... announces the list of stocks featured in the Analyst Blog. Every ... events impacting stocks and the financial markets. Stocks recently featured in ... Report ), Celgene (Nasdaq: CELG - Free Report ... ), Market Vectors Biotech ETF (AMEX: BBH - ... XBI - Free Report ). Today, Zacks is ...
(Date:10/31/2014)... 31, 2014 /CNW Telbec/ - Ergoresearch Ltd ... plan, for accelerated growth in terms of sales and ... reached $17,862,341. Net income amounted to $1,230,153. The EBITDA ... first time in the Company,s history. With ... the forces of its subsidiaries, merging in September 2014 ...
(Date:10/31/2014)... -- Though therapies are in their nascent phase, sales ... annual increase of 16.2% over the 2010-2020 period, reaching ... to Kalorama Information,s report, Stem Cell Therapeutics Markets ... have gained or are expected to gain approval from ... ever more complicated conditions, stem cell therapies hold the ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
... 20 Santaris Pharma announced today that,the fourth ... In the USA,several patients with cancer have now ... jointly developed by Santaris Pharma and Enzon,Pharmaceuticals. The ... Pharma­ceutical,s Investigational New Drug (IND) application,for the use ...
... Expands Overseas TBI TrialCOSTA MESA, Calif., March 19 ... that the company has received a letter from the ... forward" as a basis to resume clinical studies of ... therapeutic oxygen carrier.The letter was in response to the ...
Cached Medicine Technology:Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 2Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 3
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, 2014 (HealthDay ... is nothing new. The first kidney transplant took place ... and the first human heart transplant in 1967. By 2010, ... face. One major organ still eludes the transplant surgeon, ... U.S. scientists has its way, that dream may become reality, ...
(Date:10/31/2014)... year, people across the United States spend an estimated ... which costs $522 billion, according to new research. ... the time and wages that caregivers give up every ... daily activities. The study authors said the significant financial ... flexibility policies. "Our findings provide a new and ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... research group at the DFG Research Center for Regenerative ... Dresden (CRTD) demonstrated for the first time the in ... three dimensions from mouse embryonic stem cells. Correct spatial ... the dorsal/ventral axis was observed., This study has been ... Cell Reports " on 30.10.2014 ., For many years ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
Breaking Medicine News(10 mins):Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Facebook Websites In Thirty-Seconds 2
... clarify the disease,s connection to obesity , , TUESDAY, Dec. 30 ... their blood appear to be more likely to develop breast ... might be the link between obesity and breast cancer, say ... York City. High insulin levels have already been associated with ...
... variant had cancer as well as idiopathic pulmonary fibrosis, study ... mutation in a gene previously found to help protect the ... and some inherited cases of a lethal lung disease affecting ... in the SFTPA2 gene have been found in ...
... resident Gary Balady, MD, a cardiologist in the Division ... of medicine at the Boston University School of Medicine ... by Castle Connolly Medical Ltd. , The America,s Top ... is a trusted and authoritative resource for identifying top ...
... cruciate ligament (ACL) reconstruction can be difficult, but a review of ... edition of Sports Health: A Multidisciplinary Approach highlights how the use ... issues. , ... Rosemont, IL (Vocus) December 30, 2008 ...
... Treat Diseases (HTDS) www.htdsmedical.com (temporary site up ... it has registered with Pink Sheets for its back ... information including updating last 2 years financial statements. The ... a "Yield" rank from the current "STOP" no information ...
... with fish oil can improve health and cholesterol levels, however, new ... Approach highlights the effects of the omega fish oil on professional ... ... -- Researchers have firmly established that supplementing a diet with fish ...
Cached Medicine News:Health News:High Insulin May Boost Odds of Breast Cancer 2Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:BMC, Boston University School of Medicine cardiologist named 1 of America's Top Doctors 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 3Health News:Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players 2Health News:Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: